

# David C McGowan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4195984/publications.pdf>

Version: 2024-02-01

26  
papers

864  
citations

430874

18  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1105  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4853-4858.      | 2.2  | 130       |
| 2  | Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5671-5686.   | 6.4  | 64        |
| 3  | Versatile Multicomponent Reaction Macrocyclic Synthesis Using $\alpha$ -Isocyano- $\gamma$ -carboxylic Acids. <i>Organic Letters</i> , 2015, 17, 4980-4983.   | 4.6  | 55        |
| 4  | 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2492-2496.  | 2.2  | 52        |
| 5  | Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck: Synthesis, SAR, and in Vivo Antiinflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4981-4991.   | 6.4  | 51        |
| 6  | Structure-Based Design of a Benzodiazepine Scaffold Yields a Potent Allosteric Inhibitor of Hepatitis C NS5B RNA Polymerase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4099-4102.   | 6.4  | 49        |
| 7  | Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2305-2309.                                    | 2.2  | 45        |
| 8  | Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4437-4443.   | 2.2  | 37        |
| 9  | Structure-Based Macrocyclization Yields Hepatitis C Virus NS5B Inhibitors with Improved Binding Affinities and Pharmacokinetic Properties. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 4637-4640.  | 13.8 | 33        |
| 10 | Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1880-1892.   | 6.4  | 32        |
| 11 | Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7936-7949.  | 6.4  | 32        |
| 12 | Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2299-2304.  | 2.2  | 31        |
| 13 | Alkynylpyrimidine Amide Derivatives as Potent, Selective, and Orally Active Inhibitors of Tie-2 Kinase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 627-640.  | 6.4  | 28        |
| 14 | Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5095-5100.   | 2.2  | 27        |
| 15 | Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6189-6193.   | 2.2  | 24        |
| 16 | Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure-Activity Relationships, and Inhibition of in Vivo T Cell Activation. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1681-1694. | 6.4  | 21        |
| 17 | 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6236-6246.  | 6.4  | 21        |
| 18 | Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9680-9690.  | 6.4  | 21        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research. Current Topics in Medicinal Chemistry, 2019, 19, 2228-2238.   | 2.1 | 21        |
| 20 | Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library. Antiviral Research, 2017, 147, 149-158.  | 4.1 | 17        |
| 21 | Regulation of gene transcription by thyroid hormone receptor $\beta^2$ agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE, 2020, 15, e0240338.           | 2.5 | 17        |
| 22 | Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4431-4436.    | 2.2 | 15        |
| 23 | Identification and Optimization of Pyrrolo[3,2- <i>d</i> ]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B. Journal of Medicinal Chemistry, 2017, 60, 6137-6151. | 6.4 | 15        |
| 24 | Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 711-719.  | 2.2 | 12        |
| 25 | Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3216-3221.                                      | 2.2 | 9         |
| 26 | Synthesis and evaluation of novel HCV replication inhibitors. Molecular Diversity, 2017, 21, 475-481.  | 3.9 | 2         |